T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a report issued on Tuesday morning. The firm issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Trading Up 7.3 %

Shares of NASDAQ:TTOO opened at $0.25 on Tuesday. The firm’s 50 day moving average price is $0.41 and its 200-day moving average price is $2.00. T2 Biosystems has a twelve month low of $0.22 and a twelve month high of $6.95.

Institutional Investors Weigh In On T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC bought a new position in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned 9.49% of T2 Biosystems at the end of the most recent quarter. 23.18% of the stock is currently owned by hedge funds and other institutional investors.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.